Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1045 in Combination With Rituximab in 1L Follicular Lymphoma
NCT07634471Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2026
- Primary completion
- Jul 2032
- Countries
- 13
01
Overview
A Phase 3 trial of CN201 in follicular lymphoma (FL), sponsored by Merck & Co.. Started Jun 2026; status: recruiting.
02
Drugs
CN201
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT07634471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07634471.